Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Assay Predicts Response to Flu Vaccine

By LabMedica International staff writers
Posted on 21 Jul 2011
An assay predicts, within a few days, whether an individual will produce high levels of antibodies against an influenza vaccine.

Scientists scanned the extent to which selected genes are turned on in white blood cells and predicted, on day three, with up to 90% accuracy, who would make high levels of antibodies against a standard flu vaccine four weeks later. More...


The approach, which involved immunology, genomics, and bioinformatics, was pioneered by Bali Pulendran, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine (Atlanta, GA, USA) and Yerkes National Primate Research Center (Atlanta, GA, USA) when studying the yellow fever vaccine. He worked with colleagues from the Georgia Institute of Technology (Atlanta, GA, USA), Duke University (Durham, NC, USA), Dana Farber Cancer Institute, Institute for Systems Biology (Boston, MA, USA) and the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) to extend this approach to the influenza vaccine, against which many people have some preexisting immunity.

Prof. Pulendran was senior author of a paper reporting the results of the flu vaccine study that were published online on July 10, 2011, in the journal Nature Immunology.

The predictive model is based on a series of clinical studies during the annual flu seasons in 2007, 2008, and 2009. Healthy young adults were vaccinated with a standard flu shot (trivalent inactive vaccine). Others were given live attenuated vaccine nasally.

The activity levels of all human genes were surveyed in blood samples from the volunteers. The activity of many genes involved in innate immunity, interferon, and reactive oxygen species signaling changed after flu vaccination. The team also identified genes in the unfolded protein response, necessary for cells to adapt to the stress of producing high levels of antibodies.

A computer model was developed using the gene activity data from one season to identify small groups of genes that can predict high and low responders. Later, the scientists examined whether the model could forecast who would be high or low responders in two other flu seasons.

"The main goal of our study was to demonstrate the feasibility of predicting how strongly a vaccine will stimulate the immune system," said Prof. Pulendran "Along the way, we have developed an assay that focuses on a handful of genes, which could be the basis for a customized vaccine chip to make these predictions cost-effectively."

Related Links:
Emory University School of Medicine
Yerkes National Primate Research Center
National Institute of Allergy and Infectious Diseases


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.